The MEA frozen tissues samples market has been segmented into the UAE, Saudi Arabia, South Africa, and Rest of MEA. During the forecast period, the region is expected to continue to see steady growth due to growing presence of key market players through expansion of distribution network and rising number of biobanks and demand for frozen tissue samples for research. Frozen tissue is the preferred biospecimen for contemporary testing as it produces a high yield of high-quality nucleic acids and proteins. Frozen biospecimen collection has mostly been the domain of research programs; however, next-generation testing is being adopted in daily clinical care, implying that frozen tissue collections may become a part of routine tests for the diagnosis of cancer or certain other disorders.
Continuous improvements in medical science and R&D extend longevity and improve quality of life. Frozen tissue samples are majorly designed to diagnose and treat various types of cancer. At the same time, new candidates are also being explored for other indications, such as infectious diseases and central nervous system disorders.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA frozen tissues samples market at a notable CAGR during the forecast period.
The MEA frozen tissues samples market is segmented on the basis of product type, application, end user, and country. The market, based on product, is segmented into frozen normal tissues samples, frozen tumor tissues samples, and frozen diseased tissue samples. The frozen tissue tumor samples segment held the largest share of the market in 2021. Based on application, the MEA frozen tissues samples market is segmented into disease diagnosis and treatment, cancer and other diseases research, and morphological analysis. In 2021, the cancer and other diseases research segment accounted for the largest share of the market. The MEA frozen tissues samples market, by end user, is segmented into academic and research institutes, hospitals and clinics, diagnostic centers, and others. In 2021, the academic and research institutes segment held the largest market share. Based on country, the MEA frozen tissues samples market is segmented into Saudi Arabia, South Africa, UAE, and Rest of MEA.
AMS Biotechnology Ltd.; Audubon Bioscience Co; Bay Biosciences LLC; BioChain Institute Inc.; OriGene Technologies, Inc.; ProteoGenex, Inc.; REPROCELL Inc.; and ZenBio, Inc. are among the leading companies in the MEA frozen tissues samples market.